Meiogenix

Paris, France Founded: 2010 • Age: 16 yrs
Novel breeding technologies for crop plants are developed.

About Meiogenix

Meiogenix is a Healthcare company based in Paris (France) founded in 2010. Novel breeding technologies for crop plants are developed. It operates in the Healthcare and Agriculture sectors. Meiogenix has raised $13 million across 3 funding rounds from investors including ARE, Bpifrance and Kurma Partners. Its chief executive, as recorded, is Luc Mathis. Meiogenix offers products and services including Chromosome Editing. Its focus areas include Life Sciences, Genomics, Applied Genomics and Agrigenomics. Its legal entity is Meiogenix Inc.

Company details

Meiogenix was founded in 2010 and is based in Paris, France. Operations focus on the agricultural biotechnology sector, where novel breeding technologies for crop plants are developed. A fusion protein platform is utilized to enhance recombination rates in cold regions. Solutions aimed at improving crop resilience, quality, and yield are pursued through these technologies.

  • Headquarters Paris, France
  • Sectors
    Healthcare
    Agriculture
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website meiogenix.com
  • Social LinkedIn
  • Legal Name Meiogenix Inc.
Key Metrics
  • Total Equity Funding
    $13M (USD)

    in 3 rounds

  • Latest Funding Round
    $13M (USD), Series A

    Dec 2021

  • Investors
    ARE

    & 5 more

Products & Services of Meiogenix

Meiogenix offers a comprehensive portfolio of products and services, including Chromosome Editing.

Chromosome Editing
Genetic Technology

Edits crop chromosomes to unlock genetic diversity for addressing farming challenges.

Funding Insights of Meiogenix

Meiogenix has successfully raised a total of $13M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $13 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $13M
  • Total Rounds 3
  • Last Round Series A β€” $13M
  • Investors Count 6

All 3 funding rounds of Meiogenix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2021$13MSeries A–Sofinnova Partners
Apr 2016$1.6MGrant––
–
Nov 2010Series A––
Valuation history

6 investors in total: 6 institutional.

Investors in Meiogenix

Meiogenix has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Bpifrance and Kurma Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Sofinnova Partners is focused on life sciences and healthcare investments.
sofinnovapartners.comParis, France
Early-stage VC firm focused on life science startups
genoavc.comSan Francisco, United States
Investing in Life Sciences sectors like Healthcare and Biotechnology.
casdincapital.com
Biotech startups are funded through venture capital in life sciences.
2009kurmapartners.comParis, France
Corporate consultancy, advisory, and funding services are provided to businesses.
2012bpifrance.comMaisons Alfort, France
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
1994are.comPasadena, United States
Premium access

Investor details for Meiogenix

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Meiogenix

10 people are tracked at Meiogenix (3 in leadership, 6 in board & advisors, 1 in team).

NameRoleGroup
Luc Mathis
CEOLeadership
Gaganpreet Sidhu
Chief Technology OfficerLeadership
Virginie Alexanian
CFOLeadership
Benoit Barteau
DirectorBoard & advisors
Johan Cardoen
ChairmanBoard & advisors
Wojtek P. Pawlowski
Scientific AdvisorBoard & advisors
Michael Krel
DirectorBoard & advisors
Jenny Rooke
DirectorBoard & advisors
Neal Gutterson
DirectorBoard & advisors
Alain Nicolas
CSOTeam
Premium access

Complete people profiles for Meiogenix

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Meiogenix

3 dated milestones of Meiogenix across 11 years, from founding to its latest funding, stage changes and deals.

  1. Founded Meiogenix is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series A, of $13.0M.

Web traffic of Meiogenix

The website of Meiogenix (meiogenix.com) receives about 1.8K visits a month.

  • Monthly visits
    1.8K

    ▲ 46.6% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Meiogenix

Premium access

Complete news archive for Meiogenix

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Meiogenix

Meiogenix was founded in 2010.

Meiogenix is headquartered in Paris, France.

Luc Mathis is the CEO of Meiogenix, as recorded in our data.

Meiogenix is a funded company, having raised a total of $13M across 3 funding rounds to date.

Meiogenix was founded in 2010 and is based in Paris, France. Operations focus on the agricultural biotechnology sector, where novel breeding technologies for crop plants are developed. A fusion protein platform is utilized to enhance recombination rates in cold regions. Solutions aimed at improving crop resilience, quality, and yield are pursued through these technologies.

Meiogenix offers Chromosome Editing.

Meiogenix has 6 investors. Key investors include ARE, Bpifrance, Kurma Partners, Sofinnova Partners, and Genoa Ventures.

Meiogenix operates through Meiogenix Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available